Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Targeted Alpha-Therapy Market Poised To Hit $2.25 Billion By 2030 With A 17% CAGR
The targeted alpha-therapy market size has shown significant expansion over recent years. It is anticipated to grow from $1.03 billion in 2025 to $1.2 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.2%. Historically, this growth can be linked to advancements in nuclear medicine research, an escalating need for treatments in advanced cancers, the increase in radiopharmaceutical clinical trials, the availability of medical isotopes, and the rising acceptance of targeted radiation therapy.
The targeted alpha-therapy market size is anticipated to undergo significant expansion in the coming years. It is projected to increase to $2.25 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 17.0%. This growth during the forecast period is driven by factors such as greater investment in isotope manufacturing infrastructure, a rise in the adoption of personalized radiotherapy, the extension of targeted alpha therapies into new indications, increasing regulatory support for radiopharmaceuticals, and enhanced collaboration between nuclear and oncology specialists. Prominent trends expected in this period include the escalating development of alpha-emitting radiopharmaceuticals, a growing utilization of targeted radioligand therapies, a heightened focus on precision radiation delivery, the expansion of isotope production capabilities, and improved integration of targeting molecules.
Get A Free Sample Report With In-Depth Market Insights:
Targeted Alpha-Therapy Market Growth Catalysts And Demand Drivers
The increasing emphasis on precision medicine is anticipated to boost the expansion of the targeted alpha-therapy market in the future. Precision medicine is defined as a healthcare strategy that tailors prevention, diagnosis, and treatment according to a person’s genetic profile, lifestyle, and surroundings to achieve superior results. The rise of precision medicine is driven by the expanding access to genetic testing, which facilitates more precise diagnoses and individualized treatments, leading to better patient outcomes. Targeted alpha-therapy contributes to precision medicine by delivering highly effective alpha-emitting isotopes specifically to cancer cells, thereby allowing for personalized and accurate treatment while reducing harm to healthy tissues. For example, data from March 2024, as reported by the American Pharmaceutical Review, a US-based journal, indicates that worldwide expenditure on precision medicine treatments amounted to approximately $32 billion in 2022 and is forecast to surpass $124 billion by 2027. Consequently, the increased attention on precision medicine is fueling the growth of the targeted alpha-therapy market.
Targeted Alpha-Therapy Market Breakdown By Product Type And Application
The targeted alpha-therapy market covered in this report is segmented –
1) By Isotope Type: Actinium-225, Radium-223, Lead-212, Bismuth-213, Other Isotype Types
2) By Application: Prostate Cancer, Bone Metastases, Pancreatic Cancer, Other Applications
3) By End-User: Hospitals, Cancer Research Institutes, Specialty Clinics, Lymphoma, Other End Users
Subsegments:
1) By Actinium-225: Ac-225 Lintuzumab, Ac-225 PSMA-617, Ac-225 DOTATATE
2) By Radium-223: Radium-223 Dichloride (Xofigo)
3) By Lead-212: Pb-212 DOTAMTATE (AlphaMedix), Pb-212 TCMC-Trastuzumab
4) By Bismuth-213: Bi-213 Lintuzumab, Bi-213 DOTATOC
5) By Other Isotope Types: Thorium-227, Astatine-211, Terbium-149
Targeted Alpha-Therapy Market Trends Shaping Long-Term Demand
Leading companies in the targeted alpha-therapy market are concentrating on developing innovative solutions such as peptide receptor radionuclide therapy to enhance the efficacy of targeted cancer treatment, minimize off-target effects, and improve patient outcomes. Peptide receptor radionuclide therapy (PRRT) describes a precise cancer treatment that delivers radioactive isotopes directly to tumor cells by attaching them to peptides designed to specifically bind with receptors overexpressed on cancer cells, thereby reducing harm to healthy tissue. For instance, in February 2024, RadioMedix Inc., a US-based biotechnology company, partnered with Orano Med, a US-based pharma company, and secured the first targeted alpha therapy to achieve FDA breakthrough device designation, AlphaMedix (lead-212-Dotamtate), which aims to treat neuroendocrine tumors. It is formulated to treat advanced gastroenteropancreatic neuroendocrine tumors by delivering highly potent alpha radiation directly to cancer cells while protecting healthy tissue. Its key advantage stems from the high energy and short path length of alpha particles, which cause lethal DNA damage to tumor cells with minimal toxicity. This therapy offers a promising option for patients who are new to or have shown limited response to current beta-emitter treatments, with the objective of improving efficacy and safety in difficult-to-treat neuroendocrine tumors.
Targeted Alpha-Therapy Market Company Landscape And Competitive Strategy
Major companies operating in the targeted alpha-therapy market are Bayer Aktiengesellschaft, Novartis AG, Lantheus Holdings Inc., Telix Pharmaceuticals Limited, Eckert & Ziegler Strahlen- und Medizintechnik AG, Actinium Pharmaceuticals Inc., RayzeBio Inc., ITM Isotope Technologies Munich SE, ARTBIO Inc., AdvanCell Pty Ltd., IONETIX Corporation, Abdera Therapeutics Inc., Aktis Oncology Inc., Alpha-9 Oncology Inc., Clarity Pharmaceuticals Pty Ltd., Nucleus RadioPharma, Oncoinvent AS, PanTera, Perspective Therapeutics Inc., RadioMedix Inc.
View The Full Targeted Alpha-Therapy Market Report:
Targeted Alpha-Therapy Market Geographic Distribution And Regional Opportunities
North America was the largest region in the targeted alpha-therapy market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the targeted alpha-therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
